Research Projects & Grants

For Profit Organization

• An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants with Moderately to Severely Active Ulcerative Colitis, Role: PI, Arena Pharmaceuticals, Inc., (06/2025 - 06/2026) Status: Approved
• A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inadequate Response to Conventional Therapy, Role: PI, Celgene, Inc., (01/2026 - 01/2027) Status: Approved
• An Open-label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Who Achieved Clinical Response Following Open-label Vedolizumab Intravenous Therapy, Role: PI, Takeda America Research and Development Center Inc., (02/2026 - 02/2027) Status: Approved